Why Seres Therapeutics, Inc.’s (MCRB) Stock Is Up 5.23%
As of Thursday, September 03, Seres Therapeutics, Inc.’s MCRB share price has surged by 5.23%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Why Seres Therapeutics, Inc.’s (MCRB) Stock Is Up 5.12%
As of Friday, July 17, Seres Therapeutics, Inc.’s MCRB share price has surged by 5.12%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Seres Therapeutics, Inc.’s (MCRB) Stock Is Down 7.38%
As of Tuesday, July 14, Seres Therapeutics, Inc.’s MCRB share price has dipped by 7.38%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Seres Therapeutics, Inc.’s (MCRB) Stock Is Down 7.86%
As of Monday, July 13, Seres Therapeutics, Inc.’s MCRB share price has dipped by 7.86%, which has investors questioning if this is right time to buy.Michael Rose
Why Seres Therapeutics, Inc.’s (MCRB) Stock Is Down 7.79%
As of Friday, July 10, Seres Therapeutics, Inc.’s MCRB share price has dipped by 7.79%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | MCRB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $56.9 | $282.4 | 16% |
|
| Shares Out (Mil) | 9.7 | 54.0 | 20% |
|
| Institutional Ownership | 94.7% | 93.1% | 65% |
|
| Float (Mil) | 8.7 | 42.2 | 17% |
|
| Beta | 0.21 | 0.94 | 13% |
|
| Avg Daily Volume (000s) | 62 | 482 | 31% |
|
| Price Change (52-week) |
(69.6%) | 59.9% | 9% |
|
| Growth | MCRB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (52.5%) | 14.1% | 0% |
|
| Net Income (5yr) | 15.6% | (10.1%) | 65% |
|
| EPS (5yr) | 15.2% | 15.9% | 57 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (33.3%) | (15.6%) | 16% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($1.005) | ($3.515) | ($4.945) | |
| Month Ago EPS | ($1.635) | ($7.515) | ($6.575) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($2.370) | ($9.190) | ($10.280) | |
| Year/Year Chg | (313.8%) | (649.2%) | (877.3%) | |
| Financials | MCRB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $37 | 3% |
|
| Net Income (TTM) (Mil) | ($23) | ($43) | 23% |
|
| EPS (TTM) | ($2.410) | ($1.500) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($51) | ($31) | 9% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $45 | $4 | 38% |
|
| Enterprise Value (Q1) (Mil) | $86 | $190 | 20% |
|
| Valuation | MCRB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.63 | 2.84 | 42% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | MCRB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (18.3%) | (47.7%) | 21% |
|
| ROE | (66.6%) | (55.0%) | 13% |
|
| Liabilities to Assets | 66.0% | 29.8% | 61% |
|
| F-Score | 1 | 3 | 1% |
|
Seres Therapeutics, Inc. did not pass any screens on 9/4/2026.
